June 1 (Reuters) - Integral Diagnostics Ltd IDX.AX :
* REAFFIRMS IT WILL ACHIEVE NORMALISED FY18 NPAT GROWTH OF AROUND 20 PERCENT
* REAFFIRMS EBITDA GUIDANCE FOR FY18 OF $38 MILLION TO $39 MILLION
* BUYS GEELONG MEDICAL IMAGING; PURCHASE PRICE $4.7 MILLION ON A CASH AND DEBT FREE BASIS